培美曲塞与铂类化疗药联合使用对晚期肺腺癌患者治疗有效性与安全性研究

摘要

Objective:To study the efficiency and safety of pemetrexed combined with platinum chemotherapy in the treatment process of advanced lung adenocarcinoma .Methods:200 patients with advanced lung adenocarcino-ma treated in our hospital were considered as study object .They were divided into two groups , 102 patients were treated with docetaxel and cisplatin ( control group ) , while 98 patients were used with pemetrexed and cisplatin for treatment ( observation group ) .The clinical efficacy between the two groups was observed and compared .Results:(1) Before treatment, there was no obvious difference between the two groups including carcino -embryonic antigen (CEA), cancer antigen 125 (CA125), cytokeratin fragment antigen 21-1 (CYFRA21-1) and the scores about physical function, fatigue, nausea and vomiting, insomnia, loss of appetite, overall quality of life(P>0.05);Af-ter treatment , the index including CEA , CA125 , CYFRA21-1 and the scores about fatigue , nausea and vomiting , insomnia, loss of appetite were significantly lower in observation group compared with the control group (P>0.05), while the scores about physical function and overall quality of life were significantly higher in observation group than control group (P >0.05).(2) The effective rate in the observation group was significantly higher than the control group(P<0.05), and the progression free survival and overall survival in the observation group were significantly higher than the control group with increased adverse reaction (P<0.05).Conclusion:Pemetrexed combined with platinum chemotherapy drugs is used in the treatment process of advanced lung cancer .It can reduce the level of CEA, CA125, CYFRA21-1 with improved quality of life .The method is safe with better treatment effect .%目的:探讨培美曲塞与铂类化疗药联合使用对晚期肺腺癌患者治疗有效性与安全性.方法:研究对象为我院收治的200例晚期肺腺癌患者,分为观察组(n=98)与对照组(n=102).其中观察组患者接受培美曲塞联合顺铂进行治疗,而对照组患者接受多西他赛联合顺铂进行治疗,研究上述治疗方案对患者的治疗效果.结果:(1)两组患者治疗前癌胚抗原(CEA)、肿瘤标志物糖类抗原125(CA125)、细胞角蛋白19片段抗原(CYFRA21-1)、躯体功能、疲乏、恶心呕吐、失眠、食欲丧失、整体生活质量评分差异无统计学意义(P>0.05);观察组治疗后CEA、CA125、CYFRA21-1指标值及疲乏、恶心呕吐、失眠、食欲丧失评分值明显低于对照组(P<0.05),而观察组躯体功能、整体生活质量评分明显高于对照组(P<0.05).(2)观察组患者治疗近期有效率、无进展生存期、总生存期高于对照组患者(P<0.05),而不良反应发生率低于对照组(P<0.05).结论:培美曲塞与铂类化疗药联合使用可降低晚期肺腺癌患者CEA、CA125、CYFRA21-1水平,提高患者生活质量,疗效显著,安全可靠.